January 25, 2022 -- Harbour BioMed has successfully completed dosing of the first patient in a phase IB/IIA trial at the stage of dose expansion of its anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, HBM4003, in combination therapy with toripalimab, an antiprogrammed cell death protein 1 (PD-1) antibody, for patients suffering from advanced melanoma and solid tumors.
The antibody showed a good safety profile and strong efficacy in the monotherapy study of the phase I trial, according to the company. Harbour BioMed is seeking to conduct studies of HBM4003 in combination therapy as a treatment for multiple solid tumors, including melanoma, non-small cell lung cancer, hepatocellular carcinoma, neuroendocrine tumors, and neuroendocrine carcinoma.
HBM4003 is a fully human antiCTLA-4 monoclonal heavy chain-only antibody generated from Harbour mice. By enhancing antibody-dependent cell cytotoxicity-killing activity, the antibody can improve depletion specific to high CTLA-4 Treg cells in tumor tissues, the firm said.
Harbour BioMed is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics that are focused on immunology and oncology.